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ABSTRCT 
This study aims at determining relationship between the ABO blood group and the level of immunoglobulin 
classes in patients infected with Human immunodeficiency virus type 1 (HIV-1). One hundred and fifty three 
(153) confirmed HIV-1 positive subjects were enrolled in the study. These comprise of 62 (40.5%) males and 91 
(59.5%) females. Sex and age-matched HIV-negative control were also recruited. The subjects comprise of 
adults aged 18-55 years with 36 years as the mean age. The study was conducted at the CDC-UNTH ART clinic 
Enugu after obtaining ethical approval from the relevant authority.The total protein, globulin, albumin IgG, IgM 
and IgA were assayed for both the HIV-positive patients and control subjects. The standard tube technique for 
both cell and serum grouping was used in determining the blood groups of the patients and control group under 
the study. The total protein, albumin and immunoglobulins levels were all determined using the Roche/Hitachi 
902 automated  analyser .The assay principle of the total protein and albumin was colorimetric assay while that 
of immunoglobulins was turbidimetric.  Globulin assay was determined by finding the difference between total 
protein and albumin values. Descriptive statistics which include means, standard deviation (SD), frequency and 
percentage were used to analyze categorical and continuous variables. Differential statistics which include chi-
square was used to test association between categorical variable while two-way analysis of variance (ANOVA) 
was used to compare means of continuous variables. All analyses were done using the Statistical Package for 
Social Sciences (SPSS) software version 18.0.The mean levels of the total protein, globulin, albumin, IgG ,IgM 
and IgA for the HIV-positive subjects were 84.92g/l, 40.13g/l, 44.96g/l, 19.31g/l, 1.56g/l and 2.41g/l 
respectively. The mean levels of the total protein, globulin, albumin, IgG, IgM and IgA for the control group 
were 75.94g/l, 30.19g/l,45.80g/l, 18.78g/l, 0.88g/l, 2.12g/l respectively. Our work did not establish any 
statistically significant relationship (p<0.05) between ABO blood group and HIV infection. There is no 
significant difference in the mean levels of total protein, globulin, IgG,  IgM and IgA  across the blood groups 
(A,B,AB and O). We recommend the inclusion of IgM, IgG, IgA, globulin and total protein assays as baseline 
study in addition to the well established CD4+ cell count and viral load assay in assessing the Immune status of 
people infected with HIV at baseline. More study is recommended. 
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Introduction 
Immunoglobulins or antibodies circulate in the blood and serves the immune functions of searching out and 
neutralizing or eliminating antigens. Isotypes of immunoglobulins are of five classes namely, immunoglobulin A 
(IgA), immunoglobulin G ( IgG), immunoglobulin M (IgM), immunoglobulin D (IgD) and immunoglobulin E 
(IgE) and they fulfill different roles in immune defense. Increased polyclonal immunoglobulin may be seen with 
liver cirrhosis, infections, severe malnutrition, inflammatory disorders and autoimmune disorders while 
monoclonal increase are seen in tumors such as multiple myeloma, lymphoma and chronic lymphocytic 
leukemia. Decrease in immunoglobulin is seen in conditions such as agammaglobulinemia and chronic 
lymphoblastic leukemia. Out of the five existing isotypes of antibodies, those of HIV-1 specific antibodies are 
mostly IgG and to a lesser extent IgM and IgA (Constantine et al, 2005). The antibody response to HIV-I does 
not appear in the plasma until approximately 2 – 5 weeks after transmission. Generally neutralizing antibodies to 
HIV-I becomes detectable 12 weeks or more after transmission. HIV belongs to the retrovirus family and sub-
family lentiviridae. Two major types of HIV have been reported- HIV-1 and HIV-2. The third type, HIV-3 is not 
popular. HIV-1 is more prevalent, potent and worldwide than the others and has been used as the prototype in the 
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majority of the studies on HIV pathogenesis and treatment. HIV-1 is phylogenetically divided into three groups 
— ‘M’, ‘N’ and ‘O’, with the M group further split into 9 subtypes (A, C, D, B, H, E, F, G) and 15 circulating 
recombinant forms. Today, group M has a near global distribution, whereas groups N and O are restricted to 
individuals of West African origin. HIV-2 is also most common in individuals from West Africa and is 
composed of eight subtypes (Clades) - A, B, C, D, E, F, G,H (Sharp et al.,2011).It is widely believed that HIV-1 
and HIV 2 originated in African primates. One of the earliest observations made about AIDS is its extensive 
variation both within an individual and among host making it one of the fastest evolving of all organisms. HIV-I 
uses various mechanisms to evade the immune system including the infection and killing of CD4+ T 
lymphocytes. Immunoglobulin activation and impaired responses are co-existent features of AIDS and the 
interactions between HIV and the host responses are complex (Nagase et al., 2001). Seven distinct phases of the 
life cycle are commonly recognized; binding, fusion, reverse transcription, integration, replication, assembly and 
budding (aidsinfo, 2015). Entry of HIV into target cells (CD4+ cells) involves the: binding of virions (gp120 env 
protein) to receptors on target cells followed by fusion of the viral envelope (gp41) with the plasma membrane of 
the target cells. The binding of CD4+ cells with gp120 initiates a change in the CD4+ molecule to align gp120 
with co-receptors (these are chemokine molecules; CXCR4 and CCR5) that facilitate HIV attachment and 
fusion.  However, the virus can also infect by a different mechanism, many other types of human cells that lack 
the CD4+ molecule. This mechanism occurs via a glycolipid-type, galactosyl ceramide receptor (Constantine et 
al., 2005). A number of factors affect the risk of disease progression and they include the following - viral 
factors, host genetic factors and interactions between these two. The relationship between HIV replication and 
disease progression however is complex. For instance, disease progression is seen at significantly lower HIV 
RNA levels in women than in men (Sterling et al., 2001). In a limited number of cases, the presence of different 
HIV strains and quasispecie may explain differences in rates of disease progression. Host genetic factors further 
determine the magnitude of HIV replication. For example, individuals with mutation in the allele coding HIV 
immune co- receptors (CCR5 or CXCR4) have demonstrated delay progression/resistance to HIV/AIDS 
(Morgan et al., 2002).  
Immunoglobulin M (IgM) is pentameric and the first immunoglobulin class produced in response to an antigen 
and its high valency makes it more efficient than other isotypes in binding antigens and triggering complement. 
It is usually shortlived. IgM to HIV can be detected as early as 1-2 weeks after infection, but usually between 25 
and 33 days on the average.  
 Immunoglobulin G (IgG ) is monomeric and the major antibody in serum and non-mucosal tissues. The HIV-
specific antibodies are largely IgG. 
 Immunoglobulin A (IgA) is the predominant immunoglobulin class in external secretions. Maternal IgA 
antibodies enter cord blood via placenta microtransfusion and are of good specificity in assessing the HIV status 
of infants, 3 months of age and above (Constantine,2005).  
The results of the tests for IgG, IgA, and IgM levels are usually evaluated together. Abnormal test results usually 
indicate that there is something affecting the immune system and suggest the need for further testing. This test is 
not specifically diagnostic but can be a strong indicator of a disease or condition. It is pertinent to note that 
intravenous immunoglobulin (IVIg) is an important component in treating some immunodeficiency as well as 
autoimmune diseases. Documented studies showed that prophylaxis or treatment with IgG might be beneficial if 
sufficient levels of agent-specific antibodies were present (Kumar et al., 2006). Neutralizing serum antibody has 
the potential to prevent HIV-1 infection, as demonstrated by passive transfer of protective antibody to rhesus 
macaques challenged with simian human immunodeficiency virus (Baba et al., 2000) and had being investigated 
as a means of passive immunization for prevention and therapy. 
Approximately three hundred (300) blood group systems have been described but the ABO blood group system 
is the most important blood group system in human blood transfusion.  The discovery of ABO blood group 
system is credited to the Australian scientist Karl Landsteiner who found three (3) distinct blood types in 1900. 
Landsteiner described A, B and O while Alfred von Decastello and Adriano Sturli discovered the fourth type, 
AB, in 1902. The molecular basis of the ABO blood group system was highlighted in 1990 (Yamamoto et al, 
1990).The gene encodes a glycosyltransferase, which transfers N-acetyl D-galactosamine (group A) or D-
galactose (group B) to the nonreducing ends of glycans on glycoproteins and glycolipids. The group O 
phenotype results from inactivation of the A1 glycosyltransferase gene. Blood groups have been reported by 
many researchers in different parts of the world as factors predisposing some disease conditions.The ABO blood 
group have shown some association with various non infectious and infectious diseases. There is evidence 
supporting the view that blood group O provides a selective advantage against severe malaria (Rowe et al.,2009). 
There is paucity of information on the immunoglobulin levels in HIV patients and its relationship with ABO 
blood group.  
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This study was embarked upon with the following aims and objectives: 
  
AIMS AND OBJECTIVES 
1. To find out if there is association between HIV-1 infection and ABO blood group. 
2.  To compare the mean levels of total protein, globulin, albumin, immunoglobulins (IgG, IgM and IgA) 
in people who are seronegative and seropositive for HIV-1. 
3. To compare the mean levels of immunoglobulin classes (IgG, IgM and IgA), total protein, globulin and 
albumin in HIV-1 infected subjects of different ABO blood group. 
SAMPLE COLLECTION 
One hundred and fifty three confirmed HIV-1 positive patients aged 20-50 years were enrolled for the study. 
These comprise 62 (40.5%) males and 91 (59.5%) females. The same number of control  (non-HIV-infected) 
were also recruited. The following were excluded; the HIV-1 positive patients with co-infection of Tuberculosis, 
HCV and HBV infection, pregnant HIV positive females. 
A.Estimation of Test Parameters 
1.Immunoglobulin Estimation:This was done using automated immunoturbidimetric principle assay of 
Roche/Hitachi 902 analyzer. 
2. Total Protein Estimation:This was done using the automated biuret colorimetric assay method of 
Roche/Hitachi 902 analyzer. 
3.Albumin Estimation:This was done using automated albumin bromcresol green photometric method of 
Roche/Hitachi 902 analyzer. 
4.Globulin Estimation:This was done using the difference between total protein and albumin values. 
5.Blood Grouping:Tube technique: The standard tube technique for both cell and serum grouping was used in 
determining the blood groups of the patients under the study. 
6.HIV Infection: The diagnosis was determined by Western Blot test (Immunetics). 
B. Statistical Analysis: All analyses were done using the Statistical Package for Social Sciences (SPSS) 
software version 18.0.Chi-square was used to test association between categorical variable while two-way 
analysis of variance (ANOVA) was used to compare means of continuous variables. 
 
P value of 0.05 or less (P=<0.05) was assumed to be significant in this study. 
  
RESULT 
 
Table 1: Prevalence of HIV-1 infection and association across ABO blood group 
 
Blood group HIV + (%) HIV - (%) Total (%) 
A 31 (20.3) 32 (20.3) 63 (20.3) 
B 31 (20.3) 20 (15.2) 51 (18.5) 
AB 5 (3.3) 0 (0) 5 (2.2) 
O 86 (56.2) 101 (64.6) 187 (59.1) 
Total 153 (100) 153 (100) 306 (100) 
 
*X2 = 3.920, P = 0.270 
 
 
The above table indicates: 
 
• The prevalence rate. 
There is no significant statistical relationship or association between ABO blood group and HIV 
infection (p>0.05).  
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Table 2: Comparison of mean levels of total protein, globulin, albumin, lgG, lgM and lgA in 
      HIV positive patients across the ABO blood group  
Tests of Between-Subjects Effects
18.351a 6 3.058 1.454 .195
29.541b 6 4.923 3.144 .006
14.148c 6 2.358 2.340 .033
4497.090d 6 749.515 12.245 .000
196.662e 6 32.777 1.617 .143
5416.067f 6 902.678 10.342 .000
28981.438 1 28981.438 13782.226 .000
131.343 1 131.343 83.872 .000
418.752 1 418.752 415.584 .000
508862.023 1 508862.023 8313.502 .000
160514.685 1 160514.685 7919.791 .000
97625.133 1 97625.133 1118.459 .000
2.461 3 .820 .390 .760
.935 3 .312 .199 .897
1.543 3 .514 .511 .675
237.885 3 79.295 1.295 .277
109.677 3 36.559 1.804 .147
50.234 3 16.745 .192 .902
10.108 1 10.108 4.807 .029
21.415 1 21.415 13.675 .000
5.179 1 5.179 5.140 .024
3622.520 1 3622.520 59.183 .000
42.199 1 42.199 2.082 .150
4678.128 1 4678.128 53.596 .000
.338 2 .169 .080 .923
3.470 2 1.735 1.108 .332
5.276 2 2.638 2.618 .075
98.511 2 49.256 .805 .449
26.849 2 13.424 .662 .517
228.433 2 114.216 1.309 .272
473.133 225 2.103
352.352 225 1.566
226.715 225 1.008
13772.049 225 61.209
4560.197 225 20.268
19639.215 225 87.285
85414.529 232
791.924 232
1482.389 232
1572965.720 232
479737.060 232
338293.180 232
491.484 231
381.892 231
240.863 231
18269.139 231
4756.858 231
25055.283 231
Dependent Variable
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
lgG (g/l)
lgM (g/l)
lgA (g/l)
TP (g/l)
ALB
GLOB
Source
Corrected Model
Intercept
Bgrp
Group
Bgrp * Group
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
R Squared = .037 (Adjusted R Squared = .012)a. 
R Squared = .077 (Adjusted R Squared = .053)b. 
R Squared = .059 (Adjusted R Squared = .034)c. 
R Squared = .246 (Adjusted R Squared = .226)d. 
R Squared = .041 (Adjusted R Squared = .016)e. 
R Squared = .216 (Adjusted R Squared = .195)f. 
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Table 3: Table of the mean levels of total protein (TP), globulin, albumin, lgG, lgM and lgA in HIV positive 
patients across the ABO blood group 
 
 
Parameters 
 
Groups 
                            Blood group  
Total# A B AB O 
lgG (g/l) 
HIV + 19.2703 19.1819 18.7080 19.4136 19.3146 
Control 18.8306 18.6875 - 18.7851 18.7795 
Total* 19.1206 19.0440 18.7080 19.1796 19.1324 
lgM (g/l) 
HIV + 1.8755 1.6094 1.6300 1.4251 1.5604 
Control .7007 1.0308           - .9040 .8821 
Total* 1.4756 1.4479 1.6300 1.2311 1.3294 
lgA (g/l) 
HIV + 2.8741 2.1539 2.4460 2.3360 2.4117 
Control 1.9544 2.1133 - 2.1777 2.1227 
Total* 2.5610 2.1426 2.4460 2.2771 2.3133 
TP (g/l) 
HIV + 85.8242 85.1135 78.6800 84.8809 84.9165 
Control 74.0750 75.5333 - 76.6275 75.9443 
Total* 81.8245 82.4400 78.6800 81.8085 81.8613 
ALB 
HIV + 44.2484 44.4194 40.9400 45.6523 44.9641 
Control 45.1375 46.5500 - 45.8255 45.7962 
Total* 44.5511 45.0140 40.9400 45.7168 45.2474 
GLOB 
HIV + 41.6968 40.6903 37.7400 39.5028 40.1303 
Control 28.3312 28.8583 - 31.0824 30.1873 
Total* 37.1468 37.3884 37.7400 36.3682 36.7446 
*The row total means were compared across the blood groups 
# The column total means were compared between groups (HIV + and control (HIV -)) 
**The means in the cells are the interaction between the two factors. 
 
 
The above table shows that there is no significant difference in the mean levels of protein, Globulin, Albumin, 
lgG, lgM and lgA across the blood groups (A, B, AB and O). However, the mean levels of protein, globulin, lgG, 
lgM and lgA, except albumin were higher with significant statistical difference in HIV-1 positve patients when 
compared with control group.  
The interaction between the two factors - blood group and HIV status, does not have a significant effect on the 
levels of protein, Globulin, Albumin, lgG, lgM and lgA. This implies that whatever differences that exist in the 
levels of the parameters between the HIV positives and negatives were independent of the blood groups.  
 
 
 
DISCUSSION: 
Several workers have reported the existence of an association between blood group and diseases as shown in our 
introduction. However, our work did not establish any significant statistical relationship between ABO blood 
groups and HIV infection and this agreed with work done by Ukaejiofo and Nubila, (2006). Our work also failed 
to establish any statistical difference in the mean levels of total protein, globulin, albumin, IgG, IgM and IgA 
across the different ABO blood groups.  Higher mean levels of total protein, globulin, IgG, IgM and IgA with 
significant statistical difference (p < 0.05) were observed in the HIV-1 positive subjects when compared with the 
control group. Lower mean levels of albumin without statistical difference were recorded for the test group when 
compared with the control group This agrees with work done by Akinpelu et al, (2012) who documented 
polyclonal hyperglobulinemia in HIV-positive subjects. Our work also partially agreed with that of 
Ifeanyichukwu et al., (2009) who submitted that IgG and IgA were significantly increased in symptomatic HIV 
infection compared with asymptomatic HIV infection while the level of IgM were similar in both groups.  
Total protein is used in the diagnosis and treatment of diseases involving the liver, kidney or bone marrow and 
other diseases, thereby assessing the risk of disease progression. No significant statistical difference in mean 
levels was observed for total protein, globulin, albumin, IgG, IgM and IgA across the different ABO blood group 
of the HIV-1 positive subjects enrolled in the study.  
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CONCLUSION  
We found in this study that there is no statistical relationship between ABO blood group and HIV-1 infection 
There was also no significant difference in the mean levels of protein, Globulin, Albumin, lgG, lgM and lgA 
across the blood groups (A, B, AB and O). Higher mean levels of total protein, globulin, IgG, IgM and IgA with 
significant statistical difference (p < 0.05) were observed in the HIV-1 positive subjects when compared with the 
control group. There was no significant statistical difference in the levels of albumin between test and the control 
group   
We recommend the inclusion of IgM, IgG, IgA, globulin and total protein assays as baseline study in addition to 
the well established CD4+ cell count and viral load assay in assessing the Immune status of people infected with 
HIV at baseline. More study is recommended. 
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